These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29174506)

  • 1. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
    Qiu X; Huang Y; Wu D; Mao F; Zhu J; Yan W; Luo HB; Li J
    Bioorg Med Chem; 2018 Jan; 26(1):119-133. PubMed ID: 29174506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
    Huang XF; Cao YJ; Zhen J; Zhang DW; Kong R; Jiang WT; Xu Y; Song GQ; Ke HM; Liu L
    Bioorg Med Chem Lett; 2019 Feb; 29(3):481-486. PubMed ID: 30554955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.
    Morriello GJ; Dwyer MP; Chen Y; Ginetti AT; Xu S; Lu J; Abeywickrema P; Wang D; Crespo A; Cabalu TD; Wilson JE; Stachel SJ; Paone DV; Sinz C
    Bioorg Med Chem Lett; 2021 Jul; 44():128082. PubMed ID: 33991626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
    Zhang C; Feng LJ; Huang Y; Wu D; Li Z; Zhou Q; Wu Y; Luo HB
    J Chem Inf Model; 2017 Feb; 57(2):355-364. PubMed ID: 28055196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
    Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
    Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.
    Stachel SJ; Egbertson MS; Wai J; Machacek M; Toolan DM; Swestock J; Eddins DM; Puri V; McGaughey G; Su HP; Perlow D; Wang D; Ma L; Parthasarathy G; Reid JC; Abeywickrema PD; Smith SM; Uslaner JM
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1122-1126. PubMed ID: 29534798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE2 inhibition: potential for the treatment of cognitive disorders.
    Gomez L; Breitenbucher JG
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6522-7. PubMed ID: 24189054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Evaluation of Dihydropyranopyrazole Derivatives as Novel PDE2 Inhibitors for the Treatment of Alzheimer's Disease.
    Zhou Y; Li J; Yuan H; Su R; Huang Y; Huang Y; Li Z; Wu Y; Luo H; Zhang C; Huang L
    Molecules; 2021 May; 26(10):. PubMed ID: 34069639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
    Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease.
    Jiang MY; Han C; Zhang C; Zhou Q; Zhang B; Le ML; Huang MX; Wu Y; Luo HB
    Bioorg Med Chem Lett; 2021 Jun; 41():128016. PubMed ID: 33838306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
    Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors.
    Ho GD; Silverman L; Bercovici A; Puchalski C; Tulshian D; Xia Y; Czarniecki M; Green M; Cleven R; Zhang H; Fawzi A
    Bioorg Med Chem Lett; 1999 Jan; 9(1):7-12. PubMed ID: 9990447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Binding Free Energies of PDE2 Inhibitors. The Difficulties of Protein Conformation.
    Pérez-Benito L; Keränen H; van Vlijmen H; Tresadern G
    Sci Rep; 2018 Mar; 8(1):4883. PubMed ID: 29559702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new chemical tool for exploring the physiological function of the PDE2 isozyme.
    Chambers RJ; Abrams K; Garceau NY; Kamath AV; Manley CM; Lilley SC; Otte DA; Scott DO; Sheils AL; Tess DA; Vellekoop AS; Zhang Y; Lam KT
    Bioorg Med Chem Lett; 2006 Jan; 16(2):307-10. PubMed ID: 16275071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel urolithins derivatives as potential phosphodiesterase II inhibitors.
    Tang L; Jiang J; Song G; Wang Y; Zhuang Z; Tan Y; Xia Y; Huang X; Feng X
    Sci Rep; 2021 Dec; 11(1):23792. PubMed ID: 34893678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.
    Yang B; Hamza A; Chen G; Wang Y; Zhan CG
    J Phys Chem B; 2010 Dec; 114(48):16020-8. PubMed ID: 21077589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues.
    Abbott BM; Thompson PE
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2847-51. PubMed ID: 15125945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
    Zhu J; Yang Q; Dai D; Huang Q
    J Am Chem Soc; 2013 Aug; 135(32):11708-11. PubMed ID: 23899287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.